First Trust NYSE Arca Biotechnology Index Fund (FBT)
| Assets | $1.12B |
| Expense Ratio | 0.56% |
| PE Ratio | 25.77 |
| Shares Out | 6.75M |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +5.85% |
| Volume | 21,941 |
| Open | 163.79 |
| Previous Close | 164.02 |
| Day's Range | 163.79 - 166.78 |
| 52-Week Low | 140.36 |
| 52-Week High | 179.67 |
| Beta | 0.64 |
| Holdings | 32 |
| Inception Date | Jun 19, 2006 |
About FBT
Fund Home PageThe First Trust NYSE Arca Biotechnology Index Fund (FBT) is an exchange-traded fund that is based on the NYSE Arca Biotechnology index. The fund tracks an equal-weighted index of US biotechnology stocks. FBT was launched on Jun 19, 2006 and is issued by First Trust.
Top 10 Holdings
39.28% of assets| Name | Symbol | Weight |
|---|---|---|
| Exelixis, Inc. | EXEL | 4.43% |
| Natera, Inc. | NTRA | 4.20% |
| Neurocrine Biosciences, Inc. | NBIX | 4.03% |
| argenx SE | ARGX | 4.03% |
| Corcept Therapeutics Incorporated | CORT | 3.89% |
| ACADIA Pharmaceuticals Inc. | ACAD | 3.87% |
| Intra-Cellular Therapies, Inc. | ITCI | 3.83% |
| Gilead Sciences, Inc. | GILD | 3.70% |
| Catalyst Pharmaceuticals, Inc. | CPRX | 3.67% |
| Repligen Corporation | RGEN | 3.64% |
News
FBT: An Equal Weight Way To Play Biotech
Biotech stocks have not regained their 2021 peak levels, making them a potential catch-up trade. First Trust NYSE Arca Biotechnology Index Fund ETF is a fund that replicates the performance of the NYS...
Here are the top-performing ETFs in first half of 2023 as crypto-related funds soar
Hello! This week's ETF Wrap looks at top performers in the first half of 2023, as well as flows, as stocks rally and crypto-related funds jump so far this year.
FBT: No Great Prospects Despite Huge Price Gain Over Past One Year
Most stocks in FBT's biotechnology portfolio beat returns of S&P 500 during the past one year. FBT also registered a price growth of 15.5 percent. However, over the past five months, return has been m...
Why Now Could Be The Time To Consider Neuroscience Investments
Recognition that aging populations will give rise to new healthcare needs and heightened awareness of mental health issues are bringing renewed focus to neurological health. Recent advances in genomic...
FBT: This Biotech ETF Is Better Avoided In The Short Term
FBT doesn't pay any dividend and had a negative price growth over the short term. Barring the inverse funds, all other biotechnology ETFs had a high negative growth over the past 12 months.
FBT: A Long Term Hold If Done With Effective Hedging
FBT is a passive biotechnology ETF, which doesn't pay any dividend. Baring the past one year, FBT's price return has outperformed the S&P 500.
Biotech Innovations Remain At Forefront
The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively r...
Moving Beyond COVID In Biopharma
Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12,...
3 ETFs For AstraZeneca's $39B Alexion Pharmaceuticals Takeover
The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a $39-billion takeover of Alexio...
Biotech ETFs at multi-week highs, extending winning streak
Biotechnology exchange-traded funds outperformed Tuesday as investors focused on next-generation solutions to the coronavirus and more. The ARK Genomic Revolution ETF was up 2.2% in the early afternoo...
Biotech ETFs at two-week highs on upbeat vaccine news
Biotech exchange-traded funds got a bounce Friday from bullish news on coronavirus treatments. The ALPS Medical Breakthroughs ETF , the ARK Genomic Revolution ETF , and the First Trust NYSE Arca Biote...
Election History Says Buy Biotech Dip
Biotechnology exchange-traded funds were hot until they weren't. History indicates recent weakness in the previously high-flying group be a symptom of election year jitters and investors shouldn't ign...
Post-Pandemic Stars Could Align For This Biotech ETF
These days, it's not hard to find winners among health care exchange-traded funds and that's true of both established and rookie players.
Biotech stocks fall after Trump promises executive order drug prices
CNBC's Meg Tirrell reports on the dip in biotech stocks after President Donald Trump promised that an executive order on drug prices is coming.